Department of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
J Thorac Oncol. 2012 Feb;7(2):323-30. doi: 10.1097/JTO.0b013e3182381515.
Epidermal growth factor receptor (EGFR) mutation has been known to be associated with adenocarcinoma with bronchioloalveolar carcinoma (BAC; lepidic) feature. This study was aimed to characterize the frequency of EGFR mutations and their association with histologic subtypes in Korean nonsmall cell lung cancer (NSCLC) patients.
Three hundred eighty-two (88 biopsies and 294 resections) NSCLC patients were investigated for EGFR mutations (exons 18-21) by polymerase chain reaction and direct sequencing method. For the resected adenocarcinoma specimens, histologic subtypes were classified according to both 2004 World Health Organization classification and 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. The results were correlated with EGFR mutation and clinicopathologic features.
EGFR mutations were detected in 196 of 382 NSCLCs (51.3%) and were more frequent in women than in men (65.7% versus 34.3%, p < 0.001) and in nonsmokers than in smokers (63.4% versus 32.0%, p < 0.001). Regarding histologic subtypes of adenocarcinoma, mixed acinar and BAC pattern showed the most frequent EGFR mutation (67.6%), followed by mixed papillary and acinar (65.2%), mixed solid and acinar (38.2%), micropapillary and acinar (30.4%), and acinar and mucinous BAC (13.3%). In addition, EGFR mutations were more frequently observed in tumors with BAC or papillary components than those with mucinous BAC or solid components. Identical EGFR mutations were detected in a single tumor showing mixed histological features. EGFR protein expression was seen more frequently in tumors with EGFR mutations than those without EGFR mutations (75.3% versus 24.7%, p=0.003). EGFR mutations were significantly more common in tumors with thyroid transcription factor-1 (TTF-1) expression than those without TTF-1 (p < 0.001), and almost all (92.7%) mutated adenocarcinomas were TTF-1 positive.
The incidence of EGFR mutations is variable according to histologic subtypes, gender, and smoking history. The mixed acinar and BAC and papillary and acinar subtypes, the presence of BAC (lepidic) or papillary components, EGFR, and TTF-1 protein expression can predict higher EGFR mutation in lung adenocarcinoma. However, intratumoral heterogeneity of EGFR mutation was not found. In addition, relatively high incidence of EGFR mutations in Korean men who smoked with adenocarcinoma histology suggests that these patients should not be left behind EGFR mutation test.
表皮生长因子受体 (EGFR) 突变已被证实与具有细支气管肺泡癌 (BAC; 贴壁型) 特征的腺癌相关。本研究旨在研究 EGFR 突变及其与韩国非小细胞肺癌 (NSCLC) 患者组织学亚型的关系。
通过聚合酶链反应和直接测序方法,对 382 例 NSCLC 患者 (88 例活检和 294 例切除术) 进行 EGFR 突变 (外显子 18-21) 检测。对于切除的腺癌标本,根据 2004 年世界卫生组织分类和 2011 年国际肺癌研究协会/美国胸科学会/欧洲呼吸学会分类对组织学亚型进行分类。结果与 EGFR 突变和临床病理特征相关联。
在 382 例 NSCLC 中,196 例 (51.3%) 检测到 EGFR 突变,女性中 EGFR 突变的发生率高于男性 (65.7%对 34.3%,p < 0.001),非吸烟者中 EGFR 突变的发生率高于吸烟者 (63.4%对 32.0%,p < 0.001)。在腺癌的组织学亚型方面,混合腺泡和 BAC 模式的 EGFR 突变最为常见 (67.6%),其次是混合乳头和腺泡 (65.2%)、混合实性和腺泡 (38.2%)、微乳头和腺泡 (30.4%),以及腺泡和黏液性 BAC (13.3%)。此外,具有 BAC 或乳头成分的肿瘤中 EGFR 突变的发生率高于具有黏液性 BAC 或实性成分的肿瘤。在表现为混合组织学特征的单个肿瘤中,检测到相同的 EGFR 突变。与无 EGFR 突变的肿瘤相比,有 EGFR 突变的肿瘤中 EGFR 蛋白表达更为常见 (75.3%对 24.7%,p=0.003)。有甲状腺转录因子-1 (TTF-1) 表达的肿瘤中 EGFR 突变更为常见 (p < 0.001),几乎所有 (92.7%) 突变型腺癌都是 TTF-1 阳性。
EGFR 突变的发生率根据组织学亚型、性别和吸烟史而有所不同。混合腺泡和 BAC 以及乳头和腺泡亚型、存在 BAC (贴壁型) 或乳头成分、EGFR 和 TTF-1 蛋白表达可预测肺腺癌中 EGFR 突变的发生率更高。然而,并未发现 EGFR 突变的肿瘤内异质性。此外,韩国男性吸烟者的腺癌组织学中 EGFR 突变的发生率相对较高,提示这些患者不应忽视 EGFR 突变检测。